ConvaTec Group (LON:CTEC – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at Deutsche Bank Aktiengesellschaft in a report issued on Wednesday,Digital Look reports. They presently have a GBX 315 price target on the stock. Deutsche Bank Aktiengesellschaft’s target price would indicate a potential upside of 39.13% from the company’s current price.
CTEC has been the subject of a number of other research reports. JPMorgan Chase & Co. cut their price objective on shares of ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating for the company in a research note on Friday, May 22nd. UBS Group reissued a “buy” rating and set a GBX 375 price objective on shares of ConvaTec Group in a research report on Monday, May 18th. Berenberg Bank reissued a “buy” rating and set a GBX 340 price objective on shares of ConvaTec Group in a research note on Tuesday, April 21st. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 300 price objective on shares of ConvaTec Group in a research report on Wednesday. Finally, Peel Hunt reiterated an “add” rating and set a GBX 270 price objective on shares of ConvaTec Group in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, ConvaTec Group has a consensus rating of “Moderate Buy” and an average target price of GBX 306.
View Our Latest Report on CTEC
ConvaTec Group Stock Down 1.3%
Insiders Place Their Bets
In related news, insider Jonny Mason purchased 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were bought at an average price of GBX 201 per share, for a total transaction of £100,500. Corporate insiders own 0.98% of the company’s stock.
About ConvaTec Group
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Further Reading
- Five stocks we like better than ConvaTec Group
- AMD’s Post-Earnings Drop May Be the Opportunity Investors Wanted
- 3 Stocks That Prove the AI Trade Isn’t Over, It Moved
- The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic
- 3 Stocks Taking Very Different Routes Through the Summer Rally
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
